Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy
ConclusionsAdjuvant anti-PD-1 antibody can effectively improve the survival outcomes of HCC patients with high relapse risks after hepatectomy in this prospective observational study. This finding should be confirmed by results of the ongoing phase 3 randomized controlled trials.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Infectious Diseases | Liver | Liver Cancer | Study | Thrombosis | Urology & Nephrology